China's innovative drugs are facing price challenges, how to break the situation?

，，、E“2021100”，、、、、。

1992，，，、、，。

，，、、。

，、。，，，。

Shen Jingkang, a researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, made a summary review of the development history of China's innovative medicine, and analyzed the policies in the three stages of the development of China's innovative medicine.

For more exciting content, click "Read the original text" and watch the live video review.

Shen Jingkang, researcher at Shanghai Institute of Materia Medica, Chinese Academy of Sciences

The organizer of this summit, Mr.

Feng Shihan, President of Thermo Fisher China

In fact, in terms of supervision, the gap between China and the United States is no longer large, and the gap has basically been achieved.

China's innovative medicine, what is the entry barrier for innovation

The domestic research and development of innovative drugs is also moving step by step towards me-too and me-better.

What is innovation? Xu Zengjun, the former chief scientist of the Drug Evaluation Center of the State Food and Drug Administration, said that for innovative drugs, what is really needed is to meet unmet clinical needs and have their own clinical advantages.

Xu Zengjun, former chief scientist of the Center for Drug Evaluation of the State Food and Drug Administration

Mr.

As a world leader in the field of scientific services, Thermo Scientific has always been adhering to the concept of "rooting China and serving China" and promotes the development of Chinese innovative drugs from all dimensions.

Infinite possibilities of China's pharmaceutical innovation

The summit reminded that in the current new drug development track, double antibodies, ADC, cell and gene therapy, vaccines and antiviral drugs are hot research and development areas.

On the whole, China is still in the era of rapid development of innovative drugs.

For more exciting guest conversations, click "Read the original text" to watch the live video review.

In fact, the use of advanced equipment and cutting-edge technology in the development of innovative drugs can improve the core competitiveness of their products.

In fact, China has become the world's second largest biopharmaceutical market, and there is a large demand gap for various laboratory equipment and reagents.

In September 2020, the Suzhou plant of Thermo Fisher's China Manufacturing Center successfully expanded and became a one-off technology production base; in October 2020, Thermo Fisher's world's largest and most advanced customer experience center in Shanghai was officially inaugurated; at the end of 2020, Thermo Fisher, together with Jianxin Force, invested in the construction of a biopharmaceutical CDMO joint venture plant in Hangzhou to integrate the development and production of biological stock solutions and sterile preparations.

At the same time, from the perspective of the development of global innovative medicine, CDMO/CRO companies have penetrated into it and are an indispensable component in the development of innovative medicine.

As a world leader in the field of scientific services, Thermo Fisher Scientific acquired PPD for a total cash value of US$17.
4 billion in order to better serve customers worldwide.
PPD is a world-renowned CRO company.
The acquisition of PDD is also the clarion call for Thermo Fisher to enter the CRO field.
It also reflects Thermo Fisher's value proposition for pharmaceutical and biotechnology customers.
It is believed that after the acquisition of PPD, Thermo Fisher Scientific will provide more and better services to China Innovative Medicine.

China's innovative medicine faces price pain points

From the perspective of China's national conditions, there is a problem that cannot be avoided here.
Making innovative drugs means that the investment is larger than that of traditional drugs, so the final product price is also higher than that of traditional drugs.

In this summit [Innovator Policy Dialogue], the dialogue between BeiGene President Wu Xiaobin and Hengrui Pharmaceuticals Global R&D President Zhang Lianshan reminded that whether it is centralized procurement or medical insurance, the price of biological drugs/similar drugs will be pushed down.
All pharmaceutical companies face huge challenges to this problem.

For more exciting guest conversations, click "Read the original text" to watch the live video review.

Experts at the summit discussed this issue.
Innovative drugs reflect a kind of value.
If prices are lowered like generic drugs, then there is no room for innovation.
Relatively speaking, innovative drugs are a "luxury product" and must not be made into a stall.

China's innovative medicine prospects for the next ten years

This summit invited Liu Changxiao, an academician of the Chinese Academy of Engineering, to analyze and prospect the "biomedicine development trend in the next 10 years", and at the same time conducted an in-depth analysis of the development bottleneck in the construction of the biomedical industrial park.

Liu Changxiao, Academician of Chinese Academy of Engineering

Academician Liu stated in the report that if we want to make our own innovative drugs, we need the joint efforts of 50,000 hospitals and 5,000 pharmaceutical companies in my country.
In the decades of development of China's innovative drugs, China's top 100 pharmaceutical companies have emerged, and seven companies have entered the global top 100 R&D investment list.
Academician Liu expressed his expectation for the future: the next 10 years will usher in a bumper harvest of "innovation" in the pharmaceutical industry, and 10-15 leading domestic innovation companies and companies going global will be born.
China will truly enter the world.
The second echelon.

For more exciting guest conversations, click "Read the original text" to watch the live video review.

At present, China is in the historical process of moving from a big pharmaceutical country to a strong pharmaceutical country.
The government has also introduced policies to create an environment that encourages innovation, and promotes the development and changes from chemical drugs to biological drugs, and generic drugs to innovative drugs.
Driven by a series of development strategies, all parties involved in pharmaceutical innovation continue to gather, and local innovation capabilities continue to improve.

This time, under the guidance of the China Pharmaceutical Enterprise Management Association, Thermo Fisher Scientific and E-pharmaceutical managers co-hosted the "2021 China Pharmaceutical Innovation 100 Summit" successfully held, witnessing the rise of China’s pharmaceutical industry, bringing together China’s innovative strength, and focusing on leading Chinese pharmaceutical innovation Important force-the launch of the top 100 innovations, through the establishment of a sustainable high-end insight and experience exchange and mutual learning platform, advocates outstanding innovative ideas, gathers innovative ideas and consensus, breaks the barriers of innovative elements, helps the healthy development of Chinese pharmaceutical innovative enterprises, and optimizes innovation The ecological environment promotes the high-quality development of the industry.

At this summit, Thermo Fisher Scientific takes "cooperation to promote ecological construction and empower China's pharmaceutical innovation" as its value proposition.
By creating a sustainable and high-end industry insight and experience exchange platform, it links the core stakeholders of the industry and works together to break through innovation barriers.
, Optimizing the innovation environment, and empowering China's pharmaceutical innovation.

I also hope that in the future, more and more such high-quality summits will be successfully held to accelerate the development of China's innovative medicine!